← IMVT
IMVT— Immunovant, Inc.
MaterialsBiological Products, (No Diagnostic Substances)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Research and development | $456.7M+26.5% | $360.9M+69.5% | $212.9M+32.9% | $160.3M+57.4% | $101.8M | — | — |
| Acquired in-process research and development | $0 | $0-100.0% | $12.5M+25.0% | $10.0M | $0 | — | — |
| General and administrative | $76.2M-1.3% | $77.2M+34.8% | $57.3M+19.3% | $48.0M-11.4% | $54.2M+37.2% | $39.5M+117.7% | $18.2M |
| Total operating expenses | $532.9M+21.6% | $438.2M+55.0% | $282.7M+29.5% | $218.3M+39.9% | $156.0M+44.3% | $108.1M+63.6% | $66.1M |
| Interest income, net | -$25.3M-2.4% | -$24.7M+0.9% | -$24.9M-229.2% | -$7.6M | $0 | — | — |
| Other (income) expense, net | -$2.2M-363.1% | -$471K-146.7% | $1.0M+298.4% | $253K-67.6% | $781K+338.1% | -$328K+20.4% | -$412K |
| Loss before provision for income taxes | -$505.4M-22.4% | -$412.9M-59.6% | -$258.8M-22.7% | -$211.0M-34.5% | -$156.8M-45.5% | -$107.8M | — |
| Provision for income taxes | $215K-75.9% | $891K+57.1% | $567K+6200.0% | $9K+110.7% | -$84K+76.5% | -$358K-469.1% | $97K |
| Net loss | -$505.6M-22.2% | -$413.8M-59.6% | -$259.3M-22.9% | -$211.0M-34.6% | -$156.7M-45.9% | -$107.4M-61.8% | -$66.4M |
| Net loss per common share — basic (in dollars per share) | -$3K-1.5% | -$3K-45.2% | -$2K-9.9% | -$2K-19.6% | -$1K-17.2% | -$1K | — |
| Net loss per common share — diluted (in dollars per share) | -$3K-1.5% | -$3K-45.2% | -$2K-9.9% | -$2K-19.6% | -$1K-17.2% | -$1K | — |
| Weighted average common shares outstanding — basic (in shares) | $182.42B+20.4% | $151.57B+9.8% | $138.10B+12.2% | $123.08B+12.2% | $109.68B+25.0% | $87.76B | — |
| Weighted average common shares outstanding — diluted (in shares) | $182.42B+20.4% | $151.57B+9.8% | $138.10B+12.2% | $123.08B+12.2% | $109.68B+25.0% | $87.76B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.